Sorafenib
A protein kinase inhibitor
General information
Sorafenib is a non-specific serine/threonine protein kinase and tyrosine kinase inhibitor. It inhibits angiogenesis. Sorafenib is used as an antineoplastic drug (ChEBI). Sorafenib displayed anti-SARS-CoV-2 properties in vitro, which might root from its ability to bind ATP-binding site of DDX42 helicase, a host RNA-binding protein predicted to interact with SARS-CoV-2 RNA (Sun et al., 2021).
Sorafenib on DrugBank
Sorafenib on PubChem
Sorafenib on Wikipedia
Marketed as
NEXAVAR
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication
|
CaCo-2 cells | 15.58 | Aug/11/2020 | |
|
In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs
RNA Biophysical assay In vitro Mechanism In silico |
in silico; in vitro biophysical assay; Caco-2 cells; Huh7.5.1 cells; Calu-3 cells; A549-ACE2 cells | 38.64 | Inhibited SARS-CoV-2 infection in Huh7.5.1 cells with low cytotoxicity. Antiviral activity was observed in Caco-2, Calu-3, and A549-ACE2 cells, as well. Its activity might root from its ability to bind ATP-binding site of DDX42 helicase, which is a host RNA-binding protein predicted to interact with SARS-CoV-2 RNA. |
Feb/09/2021 |
